{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:01:07Z","timestamp":1792598467081,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82372200"],"award-info":[{"award-number":["No. 82372200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04576-z","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T04:24:43Z","timestamp":1765772683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPK\u03b1-PPAR\u03b1 axis and enhances the sensitivity of renal cell carcinoma to sunitinib"],"prefix":"10.1186","volume":"24","author":[{"given":"Shi-yu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-yuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-heng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"12","key":"4576_CR1","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1161\/CIRCRESAHA.111.255695","volume":"109","author":"H Cheng","year":"2011","unstructured":"Cheng H, Kari G, Dicker AP, Rodeck U, Koch WJ, Force T. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res. 2011;109(12):1401\u20139.","journal-title":"Circ Res"},{"issue":"25","key":"4576_CR2","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1093\/eurheartj\/ehae188","volume":"45","author":"X Zhou","year":"2024","unstructured":"Zhou X, Liu Y, Shen Y, Chen L, Hu W, Yan Y, et al. Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1alpha. Eur Heart J. 2024;45(25):2235\u201350.","journal-title":"Eur Heart J"},{"issue":"3","key":"4576_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","volume":"23","author":"JS Lam","year":"2005","unstructured":"Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005;23(3):202\u201312.","journal-title":"World J Urol"},{"issue":"2","key":"4576_CR4","first-page":"74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"4576_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"RJ Motzer","year":"1996","unstructured":"Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865\u201375.","journal-title":"N Engl J Med"},{"issue":"8","key":"4576_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S1470-2045(09)70185-8","volume":"10","author":"TK Choueiri","year":"2009","unstructured":"Choueiri TK, Bellmunt J. Sunitinib in renal-cell carcinoma: expanded indications. Lancet Oncol. 2009;10(8):740.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4576_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"4576_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nbt0605-639","volume":"23","author":"MA Branca","year":"2005","unstructured":"Branca MA. Multi-kinase inhibitors create buzz at ASCO. Nat Biotechnol. 2005;23(6):639.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"4576_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","volume":"7","author":"T Force","year":"2007","unstructured":"Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332\u201344.","journal-title":"Nat Rev Cancer"},{"issue":"187","key":"4576_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005066","volume":"5","author":"V Chintalgattu","year":"2013","unstructured":"Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013;5(187):187ra169.","journal-title":"Sci Transl Med"},{"issue":"9","key":"4576_CR11","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","volume":"20","author":"G Di Lorenzo","year":"2009","unstructured":"Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20(9):1535\u201342.","journal-title":"Ann Oncol"},{"issue":"25","key":"4576_CR12","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1200\/JCO.2010.34.4309","volume":"29","author":"CJ Richards","year":"2011","unstructured":"Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol. 2011;29(25):3450\u20136.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4576_CR13","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.7150\/thno.19551","volume":"7","author":"J Sourdon","year":"2017","unstructured":"Sourdon J, Lager F, Viel T, Balvay D, Moorhouse R, Bennana E, et al. Cardiac metabolic deregulation induced by the tyrosine kinase receptor inhibitor sunitinib is rescued by endothelin receptor antagonism. Theranostics. 2017;7(11):2757\u201374.","journal-title":"Theranostics"},{"issue":"9604","key":"4576_CR14","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011\u20139.","journal-title":"Lancet"},{"issue":"10","key":"4576_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79(10):1135\u201346.","journal-title":"Drugs"},{"issue":"12","key":"4576_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101334","volume":"4","author":"Q Wu","year":"2023","unstructured":"Wu Q, Yao Q, Hu T, Yu J, Jiang K, Wan Y, et al. Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2. Cell Rep Med. 2023;4(12):101334.","journal-title":"Cell Rep Med"},{"issue":"4","key":"4576_CR17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s12265-021-10192-y","volume":"15","author":"K Wang","year":"2022","unstructured":"Wang K, Li Z, Sun Y, Liu X, Ma W, Ding Y, et al. Dapagliflozin improves cardiac function, remodeling, myocardial apoptosis, and inflammatory cytokines in mice with myocardial infarction. J Cardiovasc Transl Res. 2022;15(4):786\u201396.","journal-title":"J Cardiovasc Transl Res"},{"issue":"21","key":"4576_CR18","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1161\/CIRCULATIONAHA.119.043053","volume":"141","author":"Z Ren","year":"2020","unstructured":"Ren Z, Yu P, Li D, Li Z, Liao Y, Wang Y, et al. Single-cell reconstruction of progression trajectory reveals intervention principles in pathological cardiac hypertrophy. Circulation. 2020;141(21):1704\u201319.","journal-title":"Circulation"},{"issue":"7","key":"4576_CR19","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200243R","volume":"36","author":"Z Yang","year":"2022","unstructured":"Yang Z, Li T, Xian J, Chen J, Huang Y, Zhang Q, et al. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2alpha signaling pathway in arrhythmogenic cardiomyopathy. FASEB J. 2022;36(7):e22410.","journal-title":"FASEB J"},{"key":"4576_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110821","volume":"132","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF, et al. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed Pharmacother. 2020;132:110821.","journal-title":"Biomed Pharmacother"},{"key":"4576_CR21","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.12659\/MSM.902530","volume":"23","author":"H Kuang","year":"2017","unstructured":"Kuang H, Liao L, Chen H, Kang Q, Shu X, Wang Y. Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma. Med Sci Monit. 2017;23:3737\u201345.","journal-title":"Med Sci Monit"},{"issue":"1","key":"4576_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1158\/0008-5472.CAN-21-3432","volume":"83","author":"Y Pan","year":"2023","unstructured":"Pan Y, Lu X, Shu G, Cen J, Lu J, Zhou M, et al. Extracellular vesicle-mediated transfer of LncRNA IGFL2-AS1 confers sunitinib resistance in renal cell carcinoma. Cancer Res. 2023;83(1):103\u201316.","journal-title":"Cancer Res"},{"issue":"9","key":"4576_CR23","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/cvr\/cvae077","volume":"120","author":"M Hu","year":"2024","unstructured":"Hu M, Zhang X, Hu C, Ma ZG, Wang SS, Teng T, et al. Isthmin-1 alleviates cardiac ischaemia\/reperfusion injury through cGMP-PKG signalling pathway. Cardiovasc Res. 2024;120(9):1051\u201364.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"4576_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.037455","volume":"14","author":"M Hu","year":"2025","unstructured":"Hu M, Huang SY, Gao YP, Hu YX, Wang SS, Teng T, et al. KLF12 aggravates angiotensin II-induced cardiac remodeling in male mice by transcriptionally inhibiting SMAD7. J Am Heart Assoc. 2025;14(3):e037455.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"4576_CR25","first-page":"2682","volume":"15","author":"M Hu","year":"2024","unstructured":"Hu M, Zhang X, Gao YP, Hu YX, Teng T, Wang SS, et al. Isthmin-1 improves aging-related cardiac dysfunction in mice through enhancing glycolysis and SIRT1 deacetylase activity. Aging Dis. 2024;15(6):2682\u201396.","journal-title":"Aging Dis"},{"issue":"1","key":"4576_CR26","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41467-023-39159-0","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Hu C, Ma ZG, Hu M, Yuan XP, Yuan YP, et al. Tisp40 prevents cardiac ischemia\/reperfusion injury through the hexosamine biosynthetic pathway in male mice. Nat Commun. 2023;14(1):3383.","journal-title":"Nat Commun"},{"issue":"1","key":"4576_CR27","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1038\/s41467-022-33323-8","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang F, Liu Y, Ni F, Jin J, Wu Y, Huang Y, et al. BNC1 deficiency-triggered ferroptosis through the NF2-YAP pathway induces primary ovarian insufficiency. Nat Commun. 2022;13(1):5871.","journal-title":"Nat Commun"},{"issue":"1","key":"4576_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405083","volume":"12","author":"S Huang","year":"2025","unstructured":"Huang S, Qin X, Fu S, Hu J, Jiang Z, Hu M, et al. STAMBPL1\/TRIM21 balances AXL stability impacting mesenchymal phenotype and immune response in KIRC. Adv Sci. 2025;12(1):e2405083.","journal-title":"Adv Sci"},{"issue":"2","key":"4576_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ejca.2013.08.021","volume":"50","author":"AM Molina","year":"2014","unstructured":"Molina AM, Lin X, Korytowsky B, Matczak E, Lechuga MJ, Wiltshire R, et al. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer. 2014;50(2):351\u20138.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4576_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01549-1","volume":"21","author":"Y Chen","year":"2022","unstructured":"Chen Y, Lu Z, Qi C, Yu C, Li Y, Huan W, et al. N(6)-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma. Mol Cancer. 2022;21(1):111.","journal-title":"Mol Cancer"},{"issue":"5","key":"4576_CR31","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1080\/15548627.2021.1965712","volume":"18","author":"Z Xu","year":"2022","unstructured":"Xu Z, Jin Y, Gao Z, Zeng Y, Du J, Yan H, et al. Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. Autophagy. 2022;18(5):1152\u201373.","journal-title":"Autophagy"},{"issue":"8","key":"4576_CR32","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.7150\/thno.49837","volume":"11","author":"J Sourdon","year":"2021","unstructured":"Sourdon J, Facchin C, Certain A, Viel T, Robin B, Lager F, et al. Sunitinib-induced cardiac hypertrophy and the endothelin axis. Theranostics. 2021;11(8):3830\u20138.","journal-title":"Theranostics"},{"issue":"9","key":"4576_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1161\/CIRCULATIONAHA.118.039262","volume":"140","author":"Y Li","year":"2019","unstructured":"Li Y, Chen B, Yang X, Zhang C, Jiao Y, Li P, et al. S100a8\/a9 signaling causes mitochondrial dysfunction and cardiomyocyte death in response to ischemic\/reperfusion injury. Circulation. 2019;140(9):751\u201364.","journal-title":"Circulation"},{"issue":"11","key":"4576_CR34","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJMra063052","volume":"356","author":"S Neubauer","year":"2007","unstructured":"Neubauer S. The failing heart\u2013an engine out of fuel. N Engl J Med. 2007;356(11):1140\u201351.","journal-title":"N Engl J Med"},{"key":"4576_CR35","unstructured":"White C. Generic distributors should not assume bioequivalency. Am Pharm. 1986;NS26(11):6;16."},{"key":"4576_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107705","volume":"219","author":"S Jamwal","year":"2021","unstructured":"Jamwal S, Blackburn JK, Elsworth JD. PPARgamma\/PGC1alpha signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacol Ther. 2021;219:107705.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"4576_CR37","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/nm.2439","volume":"17","author":"G Haemmerle","year":"2011","unstructured":"Haemmerle G, Moustafa T, Woelkart G, Buttner S, Schmidt A, van de Weijer T, et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med. 2011;17(9):1076\u201385.","journal-title":"Nat Med"},{"issue":"9","key":"4576_CR38","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1172\/JCI79964","volume":"125","author":"X Liao","year":"2015","unstructured":"Liao X, Zhang R, Lu Y, Prosdocimo DA, Sangwung P, Zhang L, et al. Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis. J Clin Invest. 2015;125(9):3461\u201376.","journal-title":"J Clin Invest"},{"issue":"36","key":"4576_CR39","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1093\/eurheartj\/ehab503","volume":"42","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Ling S, Li J, Zhong G, Du R, Li Y, et al. 3\u2032 untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein. Eur Heart J. 2021;42(36):3786\u201399.","journal-title":"Eur Heart J"},{"issue":"1","key":"4576_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-021-00547-y","volume":"11","author":"KL Tsai","year":"2021","unstructured":"Tsai KL, Hsieh PL, Chou WC, Cheng HC, Huang YT, Chan SH. Dapagliflozin attenuates hypoxia\/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK. Cell Biosci. 2021;11(1):44.","journal-title":"Cell Biosci"},{"issue":"1","key":"4576_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI73943","volume":"125","author":"S Lavandero","year":"2015","unstructured":"Lavandero S, Chiong M, Rothermel BA, Hill JA. Autophagy in cardiovascular biology. J Clin Invest. 2015;125(1):55\u201364.","journal-title":"J Clin Invest"},{"issue":"6","key":"4576_CR42","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1517\/13543780902980171","volume":"18","author":"HK Gan","year":"2009","unstructured":"Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opin Investig Drugs. 2009;18(6):821\u201334.","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"4576_CR43","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","volume":"19","author":"ML Telli","year":"2008","unstructured":"Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19(9):1613\u20138.","journal-title":"Ann Oncol"},{"key":"4576_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.biomaterials.2017.09.008","volume":"146","author":"Q Yang","year":"2017","unstructured":"Yang Q, Wang Y, Yang Q, Gao Y, Duan X, Fu Q, et al. Cuprous oxide nanoparticles trigger ER stress-induced apoptosis by regulating copper trafficking and overcoming resistance to sunitinib therapy in renal cancer. Biomaterials. 2017;146:72\u201385.","journal-title":"Biomaterials"},{"issue":"14","key":"4576_CR45","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1158\/1078-0432.CCR-16-2869","volume":"23","author":"V Narayan","year":"2017","unstructured":"Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, et al. Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2017;23(14):3601\u20139.","journal-title":"Clin Cancer Res"},{"issue":"32","key":"4576_CR46","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","volume":"26","author":"M Schmidinger","year":"2008","unstructured":"Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204\u201312.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4576_CR47","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1002\/cncr.23460","volume":"112","author":"AY Khakoo","year":"2008","unstructured":"Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500\u20138.","journal-title":"Cancer"},{"issue":"5","key":"4576_CR48","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13521","volume":"24","author":"JH Jang","year":"2022","unstructured":"Jang JH, Lee TJ, Sung EG, Song IH, Kim JY. Dapagliflozin induces apoptosis by downregulating cFILP(L) and increasing cFILP(S) instability in Caki-1 cells. Oncol Lett. 2022;24(5):401.","journal-title":"Oncol Lett"},{"issue":"12","key":"4576_CR49","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00228-024-03759-6","volume":"80","author":"B Xu","year":"2024","unstructured":"Xu B, Zhou J. Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system. Eur J Clin Pharmacol. 2024;80(12):1959\u201366.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"4576_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0735-1097(02)01967-8","volume":"40","author":"VG Davila-Roman","year":"2002","unstructured":"Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40(2):271\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"4576_CR51","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/cvr\/cvad100","volume":"119","author":"L Da Dalt","year":"2023","unstructured":"Da Dalt L, Cabodevilla AG, Goldberg IJ, Norata GD. Cardiac lipid metabolism, mitochondrial function, and heart failure. Cardiovasc Res. 2023;119(10):1905\u201314.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"4576_CR52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","volume":"19","author":"C Lahnwong","year":"2020","unstructured":"Lahnwong C, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T, et al. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury. Cardiovasc Diabetol. 2020;19(1):91.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"4576_CR53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S1050-1738(00)00077-3","volume":"10","author":"PM Barger","year":"2000","unstructured":"Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000;10(6):238\u201345.","journal-title":"Trends Cardiovasc Med"},{"issue":"12","key":"4576_CR54","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/ejhf.3068","volume":"25","author":"M Packer","year":"2023","unstructured":"Packer M. Qiliqiangxin: a multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms? Eur J Heart Fail. 2023;25(12):2130\u201343.","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"4576_CR55","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1161\/CIRCULATIONAHA.124.068613","volume":"150","author":"K Bonnesen","year":"2024","unstructured":"Bonnesen K, Heide-Jorgensen U, Christensen DH, Lash TL, Hennessy S, Matthews A, et al. Comparative cardiovascular effectiveness of empagliflozin versus dapagliflozin in adults with treated type 2 diabetes: a target trial emulation. Circulation. 2024;150(18):1401\u201311.","journal-title":"Circulation"},{"issue":"9","key":"4576_CR56","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.2337\/db16-0058","volume":"65","author":"SA Hawley","year":"2016","unstructured":"Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, et al. The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784\u201394.","journal-title":"Diabetes"},{"key":"4576_CR57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176708","author":"L Goedeke","year":"2024","unstructured":"Goedeke L, Ma Y, Gaspar RC, Nasiri A, Lee J, Zhang D, et al. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI176708.","journal-title":"J Clin Invest"},{"key":"4576_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.589273","volume":"12","author":"L Li","year":"2021","unstructured":"Li L, Li Q, Huang W, Han Y, Tan H, An M, et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front Pharmacol. 2021;12:589273.","journal-title":"Front Pharmacol"},{"issue":"8","key":"4576_CR59","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ijc.31193","volume":"142","author":"K Kaji","year":"2018","unstructured":"Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2018;142(8):1712\u201322.","journal-title":"Int J Cancer"},{"issue":"10","key":"4576_CR60","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","volume":"5","author":"LA Villani","year":"2016","unstructured":"Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, et al. The diabetes medication canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5(10):1048\u201356.","journal-title":"Mol Metab"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04576-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04576-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04576-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:22:39Z","timestamp":1768922559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-025-04576-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4576"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04576-z","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were approved by the ethics committee of Renmin Hospital of Wuhan University and conducted in strict accordance with the guidelines outlined in the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health (WDRM:20241005C).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}